InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic UpdateGlobeNewsWire • 05/12/22
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 PatientsBenzinga • 03/31/22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 PatientsGlobeNewsWire • 03/31/22
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis SuppurativaGlobeNewsWire • 03/17/22
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual MeetingGlobeNewsWire • 03/08/22
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis SuppurativaGlobeNewsWire • 02/28/22
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 02/16/22
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor EventsGlobeNewsWire • 01/05/22
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis SuppurativaGlobeNewsWire • 01/05/22
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)GlobeNewsWire • 11/15/21
InflaRx stock rockets on heavy volume after positive trial data on PG treatment prompts analyst upgradeMarket Watch • 10/28/21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma GangraenosumGlobeNewsWire • 10/27/21
InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19GlobeNewsWire • 10/19/21